Quick Answer
Spero Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $12.59 million for the year ending 2025.
- Spero Therapeutics, Inc. showed an increase of +3,292.5% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Spero Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $3.81 million | Q2 2019: $67.0 thousand | Q3 2019: $172.0 thousand | Q4 2019: $696.0 thousand | Q1 2020: $169.0 thousand | Q2 2020: $51.0 thousand | Q3 2020: $38.0 thousand | Q2 2021: $2.11 million | Q3 2021: $708.0 thousand | Q1 2022: $247.0 thousand | Q2 2022: $896.0 thousand | Q3 2022: $1.08 million | Q1 2023: $223.0 thousand | Q2 2023: $269.0 thousand | Q3 2023: $218.0 thousand | Q1 2024: $140.0 thousand | Q2 2024: $114.0 thousand | Q3 2024: $65.0 thousand | Q1 2025: $12.0 thousand | Q2 2025: $0.00 | Q3 2025: $0.00.
- Over the full 7 years of available data (2019 to 2025), Spero Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 165.4%.
- Historical annual values: Fiscal year 2025: $12.59 million | Fiscal year 2024: $371.0 thousand | Fiscal year 2023: $933.0 thousand | Fiscal year 2022: $2.50 million | Fiscal year 2021: $3.07 million | Fiscal year 2020: $258.0 thousand | Fiscal year 2019: $4.74 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: